Lemaitre Vascular Inc LMAT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$80.89 down $2.60, 3.11% at close Nov 6
Last close · Previous close $83.49
- Market cap
- At the Nov 6 close
- P/E ratio
- 28.38On last 12 months’ EPS
- Diluted EPS
- $2.85Last 12 months
- Dividend yield
- 1.17%Last 12 months
Price chart
$80.89down $2.60, 3.11%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$83.49Nov 5
- Volume326.44KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume300.77KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $78.22 to $118.01; now $80.89
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LMAT beat the S&P 500 in 3 of 7 periods.
| Period | LMAT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LMAT: up 2.3% S&P 500: down 5.6% | LMAT beat the S&P 500 by 7.9 percentage points Beat |
| 3M | LMAT: up 0.4% S&P 500: down 4.1% | LMAT beat the S&P 500 by 4.5 percentage points Beat |
| YTD | LMAT: up 0.5% S&P 500: up 8.7% | LMAT trailed the S&P 500 by 8.2 percentage points Trailed |
| 1Y | LMAT: down 4.5% S&P 500: up 10.9% | LMAT trailed the S&P 500 by 15.4 percentage points Trailed |
| Long term | ||
| 3Y | LMAT: up 69.3% S&P 500: up 75.0% +19.2% vs +20.5% a year | LMAT trailed the S&P 500 by 5.7 percentage points Trailed |
| 5Y | LMAT: up 55.7% S&P 500: up 67.8% +9.3% vs +10.9% a year | LMAT trailed the S&P 500 by 12.1 percentage points Trailed |
| 10Y | LMAT: up 332.9% S&P 500: up 313.1% +15.8% vs +15.2% a year | LMAT beat the S&P 500 by 19.8 percentage points Beat |
$10,000 invested in LMAT 10 years ago (Nov 4, 2016) would be worth about $43,290 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
LMAT beat the S&P 500 in 3 of 7 periods.
| Period | LMAT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LMAT: up 2.3% S&P 500: down 5.6% | LMAT beat the S&P 500 by 7.9 percentage points Beat |
| 3M | LMAT: up 0.1% S&P 500: down 4.3% | LMAT beat the S&P 500 by 4.4 percentage points Beat |
| YTD | LMAT: down 0.3% S&P 500: up 7.8% | LMAT trailed the S&P 500 by 8.1 percentage points Trailed |
| 1Y | LMAT: down 5.5% S&P 500: up 9.7% | LMAT trailed the S&P 500 by 15.2 percentage points Trailed |
| Long term | ||
| 3Y | LMAT: up 64.3% S&P 500: up 68.8% +18.0% vs +19.1% a year | LMAT trailed the S&P 500 by 4.5 percentage points Trailed |
| 5Y | LMAT: up 48.0% S&P 500: up 56.9% +8.2% vs +9.4% a year | LMAT trailed the S&P 500 by 8.9 percentage points Trailed |
| 10Y | LMAT: up 292.3% S&P 500: up 252.6% +14.6% vs +13.4% a year | LMAT beat the S&P 500 by 39.7 percentage points Beat |
$10,000 invested in LMAT 10 years ago (Nov 4, 2016) would be worth about $39,229 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$117.39
Closing high on . Now 31.1% below that record.
Split-adjusted daily closes since Oct 19, 2006.
Stock splits
LMAT hasn’t split since its price history begins in 2006.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $262.43Mup 11.8%
- Net income
- $65.67Mup 39.4%
- Diluted EPS
- $2.85up 39.0%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $54.82M | $11.14M | $0.49 |
| Q4 FY24 (Dec 31, 2024) | $55.72M | $11.18M | $0.48 |
| Q1 FY25 (Mar 31, 2025) | $59.87M | $11.01M | $0.48 |
| Q2 FY25 (Jun 30, 2025) | $64.23M | $13.78M | $0.60 |
| Q3 FY25 (Sep 30, 2025) | $61.05M | $17.36M | $0.75 |
| Q4 FY25 (Dec 31, 2025) | $64.45M | $15.58M | $0.68 |
| Q1 FY26 (Mar 31, 2026) | $66.55M | $15.68M | $0.68 |
| Q2 FY26 (Jun 30, 2026) | $70.38M | $17.05M | $0.74 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $154.42M | $26.91M | $1.25 |
| FY22 (Dec 31, 2022) | $161.65M | $20.64M | $0.93 |
| FY23 (Dec 31, 2023) | $193.48M | $30.11M | $1.34 |
| FY24 (Dec 31, 2024) | $219.86M | $44.04M | $1.93 |
| FY25 (Dec 31, 2025) | $249.60M | $57.73M | $2.52 |
Margins
- Gross 72.9%
- Operating 29.5%
- Net 25.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $73.83MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$82.98MLast 12 months
- Capital spending$9.15MLast 12 months
- 28.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $7.48MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$20.50MLast 12 months
- Total returned$20.50MLast 12 months
28% of free cash flow
Balance sheet
- $376.24MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$190.25MAs of Jun 30, 2026
- Net cash$185.99MAs of Jun 30, 2026
- 16.31As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.45As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 16.4%Last 12 months
Over the last 12 months, Lemaitre Vascular’s net income was 16.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 10.6%Last 12 months
Over the last 12 months, Lemaitre Vascular’s net income was 10.6% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.18 |
| 2017 | $0.22 |
| 2018 | $0.28 |
| 2019 | $0.34 |
| 2020 | $0.38 |
| 2021 | $0.44 |
| 2022 | $0.50 |
| 2023 | $0.56 |
| 2024 | $0.64 |
| 2025 | $1.00 |
| 2026 (to date) | $0.75 |
Dividend details
- $0.95Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield1.17%Last 12 months
- $0.25Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 16.1% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 14 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 33.3%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Lemaitre Vascular Inc
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LMAT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LMAT stock FAQ
What is LMAT stock’s price today?
Lemaitre Vascular (LMAT) traded at $80.89 at the close on , down $2.60 (3.11%) from the previous close of $83.49. Over the past 52 weeks it has traded between $78.22 and $118.01.
If you invested $1,000 in LMAT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in LMAT on would be worth about $4,329 at the close on , a total return of +332.9%. The same $1,000 would be worth $1,557 if invested five years ago, $955 if invested one year ago, and $16,135 if invested 20 years ago. Past performance doesn’t predict future returns.
What is LMAT’s P/E ratio?
LMAT trades at 28.4 times its diluted earnings over the four quarters to ($2.85 per share), at the close. (How the P/E ratio works.)
How much revenue does Lemaitre Vascular make?
Lemaitre Vascular reported $262.4 million of revenue over the four quarters to , up 11.8% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $70.4 million, up 9.6% from a year earlier.
Is Lemaitre Vascular profitable?
Yes. Lemaitre Vascular earned $65.7 million of net income over the four quarters to , a net margin of 25.0%, and its operating margin was 29.5% (what margins tell you).
What are LMAT’s earnings per share?
LMAT’s diluted earnings per share were $2.85 over the four quarters to , compared with $2.05 in the twelve months before. The latest quarter (Q2 FY26) brought $0.74 per share, against $0.60 a year earlier (how EPS works).
Does LMAT pay a dividend?
Yes. Lemaitre Vascular pays a quarterly dividend. The most recent was $0.25 per share, with an ex-dividend date of . Over the last twelve months it paid $0.95 per share, a 1.17% yield at the close, and the full-year dividend has risen 14 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($0.95 per share), and if the next 12 months match the last 12, 100 shares would receive about $95 over 12 months, and $1,000 over 12 months would take about 1,053 shares, roughly $85,177 at the close. Dividends can change.
What is LMAT’s 52-week high and low?
Over the past 52 weeks LMAT has traded as low as $78.22 and as high as $118.01. At $80.89 at the close on , it is 31.5% below that high and 3.4% above the low.
What is LMAT’s all-time high?
LMAT’s highest closing price was $117.39 on , adjusted for stock splits. At $80.89 at the close on , it is 31.1% below that record.
Has LMAT stock ever split?
No. LMAT hasn’t split since its price history begins in 2006.
How has LMAT stock performed?
Including dividends and measured to the close on , LMAT has returned +0.5% so far this year and −4.5% over the past year, and +55.7% over five years (+9.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Lemaitre Vascular in?
Lemaitre Vascular is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Massachusetts, USA.
What exchange does LMAT trade on?
Lemaitre Vascular trades on the Nasdaq under the ticker symbol LMAT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.